Triphala: An Indian Ayurvedic herbal formulation for coronavirus (SARS-CoV-2) disease (Covid-19)
This review paper updated the significance and pharmaceutical effects of Triphala as an alternative traditional herbal Indian folk medicine used as a immunity booster during the recent outbreak of coronavirus-2 (SARS-CoV-2) mutants, Delta (B.1.617.2) and Delta Plus (AY.1). The current outbreak of coronavirus-2 mutants, Delta (B.1.617.2) and Delta Plus (AY.1) is wreaking havoc in India. The new epicentre of the highest number of corona viral mutant infection cases and death rate has been recorded in Indonesia. The hallmark of the coronavirus disease is the cytokine storm, a massive cytokine and chemokine release due to an uncontrolled dysregulation of the host immune defence that causes loss of function of multiple organs and leading to death. One of the evidence to support Triphala alone inhibited the RNA viruses including human coronavirus. Triphala herbal formulation can reduce the production of progeny of human coronavirus, HCoV-NL63 particles and have an antiviral effect under in vitro conditions. In India, Triphala herbal formulation with an additional supplementation of pumpkin seeds, coconut water, sugar cane juice, Aloe vera juice, neem (Azardirachta indica) leaf juice, and melatonin rich diet has played an important role in controlling coronavirus disease than Triphala alone. However, clinical trials of Triphala with new additional supplementations is lacking for the scientific validation. On the basis literature survey, there is a ray of hope for the Triphala with additional supplementation as a new therapeutic drug for combating Covid-19 viral infections.